Boston scientific announces agreement to acquire axonics, inc.

Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction marlborough, mass. , jan. 8, 2024 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced it has entered into a definitive agreement to acquire axonics, inc. (nasdaq: axnx), a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.
BSX Ratings Summary
BSX Quant Ranking